{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-029678","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.040017+00:00","generated_at":"2026-05-19T19:59:03.077411+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vanda shareholders elect directors, ratify auditor, approve say-on-pay and equity plan amendment","bullets":["Quorum of 46,577,816 shares (79.0%) represented at June 5, 2025 annual meeting.","Directors Stephen Ray Mitchell and Tage Honoré elected with ~31.5M and ~31.3M votes for, respectively.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 43.8M for, 2.3M against.","Advisory say-on-pay approved: 28.6M for, 10.1M against, 7.7M broker non-votes.","Amendment to 2016 Equity Incentive Plan (increase shares, eliminate term) approved: 33.0M for, 5.7M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-029678","json":"https://secwatch.observer/filing/0001628280-25-029678.json","markdown":"https://secwatch.observer/filing/0001628280-25-029678.md","text":"https://secwatch.observer/filing/0001628280-25-029678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025029678/0001628280-25-029678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025029678/vnda-20250605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T19:59:03.077411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}